Diagnostic Performance of a Multiantigen Print ImmunoAssay (MAPIA) for Antibody Detection in Human Neurocysticercosis - Takeaways - MDSpire

Diagnostic Performance of a Multiantigen Print ImmunoAssay (MAPIA) for Antibody Detection in Human Neurocysticercosis

  • By

  • Luz M Toribio

  • Carolina Guzman

  • Alessandra Vasquez

  • Herbert Saavedra

  • Isidro Gonzales

  • Javier A Bustos

  • Hector H García

  • for the Cysticercosis Working Group in Peru

  • January 20, 2026

  • 0 min

Share

  • 1

    Neurocysticercosis (NCC) is a leading cause of seizures and epilepsy, complicating diagnosis due to variable symptoms and reliance on neuroimaging.

  • 2

    The enzyme-linked immunoelectrotransfer blot assay (LLGP-EITB) is the serological gold standard for NCC diagnosis but is complex and costly.

  • 3

    The Multiantigen Print Immunoassay (MAPIA) was developed using recombinant/synthetic antigens, offering a simpler and cost-effective alternative for NCC diagnosis.

  • 4

    MAPIA demonstrated a sensitivity of 97.7% and specificity of 97.4%, with 100% sensitivity for subarachnoid and parenchymal NCC with >5 cysts.

  • 5

    MAPIA's performance was comparable to LLGP-EITB, providing a reproducible and accessible tool for antibody diagnosis in resource-limited settings.

Original Source(s)

Diagnostic Performance of a Multiantigen Print ImmunoAssay (MAPIA) for Antibody Detection in Human Neurocysticercosis

  • by Luz M Toribio, Carolina Guzman, Alessandra Vasquez, Herbert Saavedra, Isidro Gonzales, Javier A Bustos, Hector H García, for the Cysticercosis Working Group in Peru

  • January 20, 2026

Related Content

Fully automated accurate patient positioning in computed tomography using anterior–posterior localizer images and a deep neural network: a dual-center study

Initial phantom studies for an office-based low-field MR system for prostate biopsy

ESR Essentials: diagnosis of hepatocellular carcinoma—practice recommendations by ESGAR